PMC:7600245 / 55136-56488 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T243","span":{"begin":243,"end":249},"obj":"Body_part"},{"id":"T244","span":{"begin":511,"end":521},"obj":"Body_part"},{"id":"T245","span":{"begin":847,"end":852},"obj":"Body_part"},{"id":"T246","span":{"begin":873,"end":878},"obj":"Body_part"},{"id":"T247","span":{"begin":961,"end":969},"obj":"Body_part"}],"attributes":[{"id":"A243","pred":"fma_id","subj":"T243","obj":"http://purl.org/sig/ont/fma/fma7203"},{"id":"A244","pred":"fma_id","subj":"T244","obj":"http://purl.org/sig/ont/fma/fma82773"},{"id":"A245","pred":"fma_id","subj":"T245","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A246","pred":"fma_id","subj":"T246","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A247","pred":"fma_id","subj":"T247","obj":"http://purl.org/sig/ont/fma/fma82768"}],"text":"It is a synthetic, small molecule and an isoxazole-carboxamide derivative (Figure 8B). It was approved by the U.S. FDA in 1998 for the oral treatment of rheumatoid arthritis [173,174,175]. It is also used off-label as a replacement therapy in kidney transplant recipients with polyomavirus BK [176] and for cytomegalovirus disease in transplant recipients resistant to standard antivirals [177]. Mechanistically, it is a disease-modifying agent with anti-inflammatory and antiproliferative effects. It inhibits pyrimidine synthesis by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase, an important enzyme in the de novo synthesis of uridine monophosphate [178]. Leflunomide is a prodrug and the active metabolite (isoxazole ring is open: teriflunomide (Aubagio)) is responsible for its activity [179]. It inhibits rapidly dividing cells such as activated T cells. It has also been found to block the transcription factor NF-κB. It also inhibits tyrosine kinase enzymes. The drug inhibits the replication of cytomegalovirus, herpes simplex virus 1, and polyomavirus BK by interfering with nucleocapsid tegumentation and virion assembly [179]. Given the above activities, a high dose of leflunomide is being evaluated for the treatment of ambulatory patients with mild COVID-19 at the University of Chicago Medicine (NCT04361214; n = 20)."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T21","span":{"begin":243,"end":249},"obj":"Body_part"}],"attributes":[{"id":"A21","pred":"uberon_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/UBERON_0002113"}],"text":"It is a synthetic, small molecule and an isoxazole-carboxamide derivative (Figure 8B). It was approved by the U.S. FDA in 1998 for the oral treatment of rheumatoid arthritis [173,174,175]. It is also used off-label as a replacement therapy in kidney transplant recipients with polyomavirus BK [176] and for cytomegalovirus disease in transplant recipients resistant to standard antivirals [177]. Mechanistically, it is a disease-modifying agent with anti-inflammatory and antiproliferative effects. It inhibits pyrimidine synthesis by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase, an important enzyme in the de novo synthesis of uridine monophosphate [178]. Leflunomide is a prodrug and the active metabolite (isoxazole ring is open: teriflunomide (Aubagio)) is responsible for its activity [179]. It inhibits rapidly dividing cells such as activated T cells. It has also been found to block the transcription factor NF-κB. It also inhibits tyrosine kinase enzymes. The drug inhibits the replication of cytomegalovirus, herpes simplex virus 1, and polyomavirus BK by interfering with nucleocapsid tegumentation and virion assembly [179]. Given the above activities, a high dose of leflunomide is being evaluated for the treatment of ambulatory patients with mild COVID-19 at the University of Chicago Medicine (NCT04361214; n = 20)."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T243","span":{"begin":153,"end":173},"obj":"Disease"},{"id":"T244","span":{"begin":164,"end":173},"obj":"Disease"},{"id":"T245","span":{"begin":1040,"end":1054},"obj":"Disease"},{"id":"T246","span":{"begin":1283,"end":1291},"obj":"Disease"}],"attributes":[{"id":"A243","pred":"mondo_id","subj":"T243","obj":"http://purl.obolibrary.org/obo/MONDO_0008383"},{"id":"A244","pred":"mondo_id","subj":"T244","obj":"http://purl.obolibrary.org/obo/MONDO_0005578"},{"id":"A245","pred":"mondo_id","subj":"T245","obj":"http://purl.obolibrary.org/obo/MONDO_0004609"},{"id":"A246","pred":"mondo_id","subj":"T246","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"It is a synthetic, small molecule and an isoxazole-carboxamide derivative (Figure 8B). It was approved by the U.S. FDA in 1998 for the oral treatment of rheumatoid arthritis [173,174,175]. It is also used off-label as a replacement therapy in kidney transplant recipients with polyomavirus BK [176] and for cytomegalovirus disease in transplant recipients resistant to standard antivirals [177]. Mechanistically, it is a disease-modifying agent with anti-inflammatory and antiproliferative effects. It inhibits pyrimidine synthesis by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase, an important enzyme in the de novo synthesis of uridine monophosphate [178]. Leflunomide is a prodrug and the active metabolite (isoxazole ring is open: teriflunomide (Aubagio)) is responsible for its activity [179]. It inhibits rapidly dividing cells such as activated T cells. It has also been found to block the transcription factor NF-κB. It also inhibits tyrosine kinase enzymes. The drug inhibits the replication of cytomegalovirus, herpes simplex virus 1, and polyomavirus BK by interfering with nucleocapsid tegumentation and virion assembly [179]. Given the above activities, a high dose of leflunomide is being evaluated for the treatment of ambulatory patients with mild COVID-19 at the University of Chicago Medicine (NCT04361214; n = 20)."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T552","span":{"begin":6,"end":7},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T553","span":{"begin":209,"end":214},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T554","span":{"begin":218,"end":219},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T555","span":{"begin":243,"end":249},"obj":"http://purl.obolibrary.org/obo/UBERON_0002113"},{"id":"T556","span":{"begin":243,"end":249},"obj":"http://www.ebi.ac.uk/efo/EFO_0000927"},{"id":"T557","span":{"begin":243,"end":249},"obj":"http://www.ebi.ac.uk/efo/EFO_0000929"},{"id":"T558","span":{"begin":419,"end":420},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T559","span":{"begin":693,"end":694},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T560","span":{"begin":711,"end":717},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T561","span":{"begin":802,"end":810},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T562","span":{"begin":847,"end":852},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T563","span":{"begin":861,"end":870},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T564","span":{"begin":871,"end":878},"obj":"http://purl.obolibrary.org/obo/CL_0000084"},{"id":"T565","span":{"begin":883,"end":886},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T566","span":{"begin":941,"end":942},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T567","span":{"begin":1055,"end":1060},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T568","span":{"begin":1117,"end":1130},"obj":"http://purl.obolibrary.org/obo/UBERON_0002199"},{"id":"T569","span":{"begin":1117,"end":1130},"obj":"http://www.ebi.ac.uk/efo/EFO_0000807"},{"id":"T570","span":{"begin":1174,"end":1184},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T571","span":{"begin":1186,"end":1187},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"It is a synthetic, small molecule and an isoxazole-carboxamide derivative (Figure 8B). It was approved by the U.S. FDA in 1998 for the oral treatment of rheumatoid arthritis [173,174,175]. It is also used off-label as a replacement therapy in kidney transplant recipients with polyomavirus BK [176] and for cytomegalovirus disease in transplant recipients resistant to standard antivirals [177]. Mechanistically, it is a disease-modifying agent with anti-inflammatory and antiproliferative effects. It inhibits pyrimidine synthesis by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase, an important enzyme in the de novo synthesis of uridine monophosphate [178]. Leflunomide is a prodrug and the active metabolite (isoxazole ring is open: teriflunomide (Aubagio)) is responsible for its activity [179]. It inhibits rapidly dividing cells such as activated T cells. It has also been found to block the transcription factor NF-κB. It also inhibits tyrosine kinase enzymes. The drug inhibits the replication of cytomegalovirus, herpes simplex virus 1, and polyomavirus BK by interfering with nucleocapsid tegumentation and virion assembly [179]. Given the above activities, a high dose of leflunomide is being evaluated for the treatment of ambulatory patients with mild COVID-19 at the University of Chicago Medicine (NCT04361214; n = 20)."}

LitCovid-PD-CHEBI

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T92","span":{"begin":522,"end":531},"obj":"http://purl.obolibrary.org/obo/GO_0009058"},{"id":"T93","span":{"begin":636,"end":645},"obj":"http://purl.obolibrary.org/obo/GO_0009058"},{"id":"T94","span":{"begin":916,"end":936},"obj":"http://purl.obolibrary.org/obo/GO_0000981"},{"id":"T95","span":{"begin":916,"end":929},"obj":"http://purl.obolibrary.org/obo/GO_0006351"},{"id":"T96","span":{"begin":1135,"end":1150},"obj":"http://purl.obolibrary.org/obo/GO_0019068"}],"text":"It is a synthetic, small molecule and an isoxazole-carboxamide derivative (Figure 8B). It was approved by the U.S. FDA in 1998 for the oral treatment of rheumatoid arthritis [173,174,175]. It is also used off-label as a replacement therapy in kidney transplant recipients with polyomavirus BK [176] and for cytomegalovirus disease in transplant recipients resistant to standard antivirals [177]. Mechanistically, it is a disease-modifying agent with anti-inflammatory and antiproliferative effects. It inhibits pyrimidine synthesis by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase, an important enzyme in the de novo synthesis of uridine monophosphate [178]. Leflunomide is a prodrug and the active metabolite (isoxazole ring is open: teriflunomide (Aubagio)) is responsible for its activity [179]. It inhibits rapidly dividing cells such as activated T cells. It has also been found to block the transcription factor NF-κB. It also inhibits tyrosine kinase enzymes. The drug inhibits the replication of cytomegalovirus, herpes simplex virus 1, and polyomavirus BK by interfering with nucleocapsid tegumentation and virion assembly [179]. Given the above activities, a high dose of leflunomide is being evaluated for the treatment of ambulatory patients with mild COVID-19 at the University of Chicago Medicine (NCT04361214; n = 20)."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T57","span":{"begin":153,"end":173},"obj":"Phenotype"}],"attributes":[{"id":"A57","pred":"hp_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/HP_0001370"}],"text":"It is a synthetic, small molecule and an isoxazole-carboxamide derivative (Figure 8B). It was approved by the U.S. FDA in 1998 for the oral treatment of rheumatoid arthritis [173,174,175]. It is also used off-label as a replacement therapy in kidney transplant recipients with polyomavirus BK [176] and for cytomegalovirus disease in transplant recipients resistant to standard antivirals [177]. Mechanistically, it is a disease-modifying agent with anti-inflammatory and antiproliferative effects. It inhibits pyrimidine synthesis by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase, an important enzyme in the de novo synthesis of uridine monophosphate [178]. Leflunomide is a prodrug and the active metabolite (isoxazole ring is open: teriflunomide (Aubagio)) is responsible for its activity [179]. It inhibits rapidly dividing cells such as activated T cells. It has also been found to block the transcription factor NF-κB. It also inhibits tyrosine kinase enzymes. The drug inhibits the replication of cytomegalovirus, herpes simplex virus 1, and polyomavirus BK by interfering with nucleocapsid tegumentation and virion assembly [179]. Given the above activities, a high dose of leflunomide is being evaluated for the treatment of ambulatory patients with mild COVID-19 at the University of Chicago Medicine (NCT04361214; n = 20)."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T411","span":{"begin":0,"end":86},"obj":"Sentence"},{"id":"T412","span":{"begin":87,"end":114},"obj":"Sentence"},{"id":"T413","span":{"begin":115,"end":188},"obj":"Sentence"},{"id":"T414","span":{"begin":189,"end":395},"obj":"Sentence"},{"id":"T415","span":{"begin":396,"end":498},"obj":"Sentence"},{"id":"T416","span":{"begin":499,"end":677},"obj":"Sentence"},{"id":"T417","span":{"begin":678,"end":817},"obj":"Sentence"},{"id":"T418","span":{"begin":818,"end":879},"obj":"Sentence"},{"id":"T419","span":{"begin":880,"end":943},"obj":"Sentence"},{"id":"T420","span":{"begin":944,"end":985},"obj":"Sentence"},{"id":"T421","span":{"begin":986,"end":1157},"obj":"Sentence"},{"id":"T422","span":{"begin":1158,"end":1352},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"It is a synthetic, small molecule and an isoxazole-carboxamide derivative (Figure 8B). It was approved by the U.S. FDA in 1998 for the oral treatment of rheumatoid arthritis [173,174,175]. It is also used off-label as a replacement therapy in kidney transplant recipients with polyomavirus BK [176] and for cytomegalovirus disease in transplant recipients resistant to standard antivirals [177]. Mechanistically, it is a disease-modifying agent with anti-inflammatory and antiproliferative effects. It inhibits pyrimidine synthesis by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase, an important enzyme in the de novo synthesis of uridine monophosphate [178]. Leflunomide is a prodrug and the active metabolite (isoxazole ring is open: teriflunomide (Aubagio)) is responsible for its activity [179]. It inhibits rapidly dividing cells such as activated T cells. It has also been found to block the transcription factor NF-κB. It also inhibits tyrosine kinase enzymes. The drug inhibits the replication of cytomegalovirus, herpes simplex virus 1, and polyomavirus BK by interfering with nucleocapsid tegumentation and virion assembly [179]. Given the above activities, a high dose of leflunomide is being evaluated for the treatment of ambulatory patients with mild COVID-19 at the University of Chicago Medicine (NCT04361214; n = 20)."}

LitCovid-PubTator

PMC:7600245 / 55136-56488 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7600245 / 55136-56488 JSON TXT